← All Quantum Biopharma LTD filings

Quantum Biopharma LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
QNTM
Quantum Biopharma LTD
20-F: Quantum BioPharma Navigates Drug Development, Crypto Volatility
Quantum BioPharma Ltd. reports a net loss of $26.96 million for 2025, driven by R&D costs and significant cryptocurrency fair value adjustments, while advancing its MS drug and settling key litigation.
NASDAQ
QNTM
Quantum Biopharma LTD
20-F/A: Quantum BioPharma Amends 20-F Filing to Include Audit Report and Financial Statement Index
Quantum BioPharma files an amendment to its 20-F annual report to include an audit report from MNP LLP and an index to the financial statements.
NASDAQ
QNTM
Quantum Biopharma LTD
20-F: Quantum BioPharma Executes Shareholder Agreement Amidst Ongoing Strategic Developments
Quantum BioPharma finalizes a shareholder agreement while navigating strategic shifts and legal challenges.
NASDAQ
QNTM
Quantum Biopharma LTD
20-F: FSD Pharma and Celly Nutrition Corp. Announce Arrangement Agreement
FSD Pharma and Celly Nutrition Corp. enter into an arrangement agreement for a reorganization transaction.